Clinical Trials in Patients with Resected Stage IIB and III Melanoma

3/8/02


Click here to start


Table of Contents

Clinical Trials in Patients with Resected Stage IIB and III Melanoma

UVA-Mel39

Risk of opening trials to those who refuse IFN

The process of informed consent

Proposal for phase II trials in patients eligible for HD-IFN?.

Benefits of system for informed consent

Alternate recommendation:  Shorten wait after refusal of IFN

Summary

Author: Craig Slingluff